Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McKesson In Final Phase Of Negotiating Fee-For-Service Contracts

This article was originally published in The Pink Sheet Daily

Executive Summary

The wholesaler anticipates 80% of compensation from manufacturers will be recorded under the new contract model by Oct. 1. Pfizer continues to be a significant holdout within the transition to fee-for-service, McKesson says.

You may also be interested in...



Wholesalers Forecast More Accurate Sell-Side Margins From Fee-For-Service Contracts

AmerisourceBergen and McKesson expect stability in manufacturer service contracts will allow for clearer focus on arrangements with customers. ABC four-point plan to enhance margins include enhancing generic programs and consolidating distribution centers.

Wholesalers Forecast More Accurate Sell-Side Margins From Fee-For-Service Contracts

AmerisourceBergen and McKesson expect stability in manufacturer service contracts will allow for clearer focus on arrangements with customers. ABC four-point plan to enhance margins include enhancing generic programs and consolidating distribution centers.

Cardinal Sees No Rx Distribution Disruptions After April 1 Fee-For-Service Deadline

Most drug manufacturers have agreed in principle to fee-for-service distribution contracts, Cardinal CEO Walter says. Negotiations are now focused on price, not the methodology for paying wholesalers, he says.

Related Content

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel